Clinical Trial Search

Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants

Primary: Sun Protection Behavior Index — 3.54; 3.37 scores on a scale

Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants

Primary: Percentage of Agreement Between the Detection of SLNs — 69.7 percentage complete agreement

Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants

Primary: Objective Response Rate (ORR) of PV-10 Treated Lesions — 51.3 percentage of participants

Primary: Number of New Onset Skin Cancer in Adult People Diagnosed With Vitiligo — 133; 812 Participants

Primary: Reach of Personalized Genomic Testing for Melanoma. — 0; 204; 0; 295 Participants

Primary: Influence of a Patient's Melanoma Diagnosis on the Survivor's and Broader Family's Skin Cancer Prevention Activity. — 24; 22; 2; 5 Participants

Primary: Number of Participants That Performed a Skin Self-Examination at 3-months — 161; 185 Participants — p=0.12

Primary: Number of Participants Who Completed SSE at Specified Time Points — 217; 242; 475; 238 Participants — p=<0.001

Primary: Resectability Rate — 8; 2 Participants

Primary: Frequency of BRAF Mutations Among Nevi — 6; 19 BRAF mutations

Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes

Primary: Recurrence-free Survival (RFS) - All Randomized Participants — NA; NA Months

Primary: Sensitivity and Specificity — 98.2; 9.5 Ratio * 100 — p=0.05

Primary: Number of Patients With Treatment-emergent Adverse Events (TEAEs) — 8; 8; 0; 0 Participants

Primary: UV-induced Oxidative Stress in Irradiated and Unirradiated Nevi — 94.6; 96.2; 33.6; 33.1 percentage of 8-OG expression in nevi — p=.65

Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change

Primary: Change in Clinician Knowledge in Melanoma Risk and Lesion Identification — 72.1; 80.8 score on a scale — p=0.05

Primary: Phase I, Number of Participants With SAE and DLT — 0; 0; 1; 0 Participants

Primary: Objective Response Rate — 1; 3; 14; 7 participants

Primary: Number of Participants With Suspicious Tumors Detected After Inspection of Problem Area and Inspection of the Full Body. — 810; 631 participants — p=<0.01

Primary: Equivalence of ICG and Real Time Lymphangiography to technetium99 and Blue Dye in Localizing Sentinel Nodes — 1.87 number of sentinel nodes per patient

Primary: Number of Genes That Showed Changes in Expression After Vitamin D Treatment — 270 number of genes

Primary: Duration of Response — 8.1 months

Primary: Determine Sensitivity of Blood-Based Assay

Primary: Clinical Response — 1; 3; 3; 2 Participants

Primary: Disease Free Survival Assessment — 32; 30; 31; 30 Participants

Primary: MTD of Photodynamic Therapy — 150 J/cm^2